MKM Partners analyst Eric Handler is keeping his Buy rating and $28 price target on Imax (IMAX), saying the stock has been "unjustly" punished for the overall 2019 box office weakness and China exposure. The analyst contends however that the company is still on track to grow its own box office sales by 10% this year, while its China box office revenue is up 20% year-to-date. Handler adds that despite these positive trends and a much lower capital intensity relative to traditional theatres, Imax valuation is in-line with AMC Entertainment (AMC) and Cinemark (CNK).